{"ticker": {"uuid": "84e01b67-8c74-45f3-addd-e5eaa6419abd", "symbol": "FBIOP", "name": "Fortress Biotech Inc Pref Series A", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Fortress Biotech Inc (FBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Fortress Biotech Inc (FBIO) has an earnings forecast score of 8.00, ranking 55th in the Pharmaceuticals industry. Analysts have set an average price target of $10.75, with most recommending a \"Buy\" trend for the stock. The expected revenue for the next quarter is $18.30M, and the", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fbio/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T06:40:18", "published_display": "19 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech (FBIO) AGM 2026 Summary", "summary": "Fortress Biotech's 2026 Annual General Meeting (AGM) was called to order by the Executive Chairman, President, and CEO. Key agenda items included the election of directors and the ratification of KPMG as the independent auditors for 2026, both of which were approved by shareholde", "url": "https://quartr.com/events/fortress-biotech-inc-fbio-agm-2026_F3HKeOdM", "source_name": "Quartr", "published_at": "2026-06-17T14:40:24", "published_display": "17 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc (FBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Fortress Biotech Inc's (FBIO) dividend and stock split history. It notes that no dividends have been distributed in the past five years. The article also details several stock merger events that occurred on October 9, 2023, with a 15:1 ratio.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fbio/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T07:40:24", "published_display": "17 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc (FBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article details Fortress Biotech Inc (FBIO)'s revenue breakdown by business segment for FY2023, FY2023Q4, FY2022, FY2022Q4, FY2021, and FY2019. Key products like Targadox\u00ae, Exelderm\u00ae, and Ximino\u00ae are highlighted with their respective revenue figures and proportions. The repo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fbio/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T07:40:24", "published_display": "17 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(FBIOP) Volatility Zones as Tactical Triggers", "summary": "This article from Stock Traders Daily provides a technical analysis of Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP), highlighting a near-term neutral outlook despite mid and long-term strength. It presents AI-generated trading stra", "url": "https://news.stocktradersdaily.com/news_release/101/FBIOP_Volatility_Zones_as_Tactical_Triggers_061526044002_1781512802.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-15T04:40:00", "published_display": "15 Jun 2026 04:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred Stock (FBIOP) Faces Resistance, Slides 2.3% in Quiet Session - Fibonacci Extension", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOREFSdWZib1NLQkowbGVLbnZFa0pvRG1RRUtlUXBJMzE2aHZ4Z01oaEFISHdYYjVOOS12Y1ZOc0xfMmpUWmhMN2tIQW9DaTZVd0FJNVNrWW9nZVBZM0E2X3NvYUlXdDdvWnh2VkFnR0FXZmF1V0wyR3h4ZjNLaDlyYUlTUDRsdFhDeHVZSXo0cFZzd3pjQVlHeEk2bEFkWGRBWW83c2tOWEgtZ1lTWTUwNi1Sd05EcGdaNGJsSHBFclNIZw?oc=5", "source_name": "newsline.com", "published_at": "2026-06-09T00:40:06+00:00", "published_display": "09 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred Stock (FBIOP) Pulls Back 2.3% as Shares Approach Key Support - Descending Triangle", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOcDV4S3RueVZmTFNIMzNXc3ZuZHY5YXI5cldiZTF3NHU3OVRVbU1nZzg1RFAxa0Z3dnhDemczLUpuUDZVNEs1ZzlvanFjQ255bkhsWF9FQ3haUk5rVTlZc0NQUUtTd3pJQnY4cHV0Rnd3TU9vd3otT19iZVJyd1VGV3lGOTFoWjI1dV9RYmlDdXlzYVJQVFRUc1l4QzdYRC0wMUpfMXZTNDJ6d2s1eHg2RmVEa3p6eGRIa1FTVHVGVVR2UEU?oc=5", "source_name": "newsline.com", "published_at": "2026-06-08T20:47:17+00:00", "published_display": "08 Jun 2026 20:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price-Driven Insight from (FBIOP) for Rule-Based Strategy", "summary": "This article provides a price-driven analysis for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (NASDAQ: FBIOP), indicating a strong overweight bias across all horizons. It identifies compelling upside potential due to the absence of resist", "url": "https://news.stocktradersdaily.com/news_release/1/Price-Driven_Insight_from_FBIOP_for_Rule-Based_Strategy_060426031002_1780557002.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-04T03:38:41", "published_display": "04 Jun 2026 03:38", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc stock (US32015L1035): Nasdaq-listed biotech moves in low-volume trade ahead of next earnings update", "summary": "Fortress Biotech Inc. (FBIO), a Nasdaq-listed biotech company, has experienced low-volume trading and modest price movements as investors await its next quarterly report. The company specializes in rare diseases and oncology, with its business model relying on commercial specialt", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/fortress-biotech-inc-stock-us32015l1035-nasdaq-listed-biotech-moves-in/69470220", "source_name": "Ad Hoc News", "published_at": "2026-06-02T10:32:40", "published_display": "02 Jun 2026 10:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred Stock (FBIOP) Surges 5.19%, Nears Key Resistance at $21.5 - Stock Picks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQVG9CdWZZa2pqZDhEa05ua0NxWkdfOU5USS03Yjk4cEJQbmtUcnU4MExJVW4wUG5VRDlvcGZKZjlwa1pmNExSUC1HZXJkSGhTUzhOSnB6NjVaLS15TzU3YTB1c1cwWTNUbVlPWlAxVWpXNWVKTGRUeUNGWHljbFNCVWJZQTEtZ2pCRW5HcnNWQVRBcldUbHEwWC1uLVZVSFZjWGRUSVpHd24zclBPaUpiSnRScW02bms?oc=5", "source_name": "newsline.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends? (FBIO)", "summary": "Fortress Biotech (FBIO) currently holds $256 million in cash and $39 million in debt, creating a strong balance sheet after a recent windfall from a Menkes disease drug sale. This positions the company to easily pay off $16 million in deferred FBIOP preferred dividends, which cou", "url": "https://seekingalpha.com/article/4910163-fortress-biotech-is-it-time-to-pay-deferred-preferred-stock-dividends", "source_name": "Seeking Alpha", "published_at": "2026-05-29T21:39:16", "published_display": "29 May 2026 21:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred (FBIOP) Rises 2.37%; Support and Resistance in Focus - Synthetic Long", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPTEp2d3hjZ2xPeEFwcDBGQmRFRnVhOFVySTNDZUYxMk9BWGRrRmhRVlJ2NUQtRVNJOTYxREdGTUt3STZzRDJIYmJkZHhJcU1wZmtZcHpTdkw4aFdzMGJ2RE95c2F2UHd0ZmtWNTZxNEZ6RkdyUHI4YTVtTFRuWUFrZzBvM2tHWmJnd1d6QktuandITTNHUjFMVzZlX09remdSNTVjU2NjY1FTeWZGZU5uRG4yRklyb21wNTNmX3RIM3dqX1h1?oc=5", "source_name": "The Legal Advocate", "published_at": "2026-05-28T20:47:08+00:00", "published_display": "28 May 2026 20:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred Shares (FBIOP) Advance 2.45% as Support Holds Near $16 - Volume Breakout Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOcjVMRy11bDFrSnpid0FoZzNMN1h0RGtnM2paYlozUVpFVDg2WkNJa1lDSWh6WFFMNFpXcXhDV3NkdVMxZFM4MW8wdjlzdjFsNFVVTDhiSHI0Y3dsenpHby11eTk1RFYwcWE0dFUxcTdITDFjUlM3dlQ2SzJPZVc2b3llNW5NWE9LdmpQb2thRUxqYXJGVDZUM0VqdDREMVZzamltLXhnT1k3OGhhOTRWdmNpbnpMRnZs?oc=5", "source_name": "newsline.com", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(FBIOP) Price Dynamics and Execution-Aware Positioning", "summary": "This article analyzes Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (NASDAQ: FBIOP) using AI models. It highlights strong sentiment supporting an overweight bias despite elevated downside risk, providing institutional trading strategies tai", "url": "https://news.stocktradersdaily.com/news_release/141/FBIOP_Price_Dynamics_and_Execution-Aware_Positioning_052426020202_1779602522.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-24T02:10:44", "published_display": "24 May 2026 02:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech to Participate in A.G.P.\u2019s Annual Virtual Healthcare Conference", "summary": "Fortress Biotech, an innovative biopharmaceutical company, announced that its Chairman, President, and CEO, Lindsay A. Rosenwald, M.D., will participate in a fireside chat at A.G.P.\u2019s Annual Virtual Healthcare Conference on Wednesday, May 20, 2026, at 12:20 PM ET. The company foc", "url": "https://www.sahmcapital.com/news/content/fortress-biotech-to-participate-in-agps-annual-virtual-healthcare-conference-2026-05-18", "source_name": "Sahm", "published_at": "2026-05-19T07:09:36", "published_display": "19 May 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock", "summary": "This article provides details about Fortress Biotech, Inc.'s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) on the Nasdaq Stock Market. It briefly mentions the availability of financial data, news, community insights, and technical analysis for this speci", "url": "https://www.tradingview.com/symbols/NASDAQ-FBIOP/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-05-18T05:39:26", "published_display": "18 May 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Fortress Biotech, Inc. \u2013 NASDAQ:FBIO", "summary": "This article provides details on the number of shareholders for Fortress Biotech, Inc. (NASDAQ:FBIO). It appears to be a stub or a placeholder, as the actual numbers for \"Period,\" \"Value,\" \"Change,\" and \"Change %\" are explicitly missing from the content. The page also includes ge", "url": "https://www.tradingview.com/symbols/NASDAQ-FBIO/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-05-17T16:39:49", "published_display": "17 May 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech stock (US32015L1035): FDA setback hits Menkes drug while investors eye next catalysts", "summary": "Fortress Biotech has faced a setback after the FDA declined to approve CUTX-101, a Menkes disease treatment from its subsidiary Cyprium Therapeutics. This regulatory decision has put pressure on the company's valuation and rare-disease pipeline, impacting speculative investors. D", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/fortress-biotech-stock-us32015l1035-fda-setback-hits-menkes-drug-while/69349115", "source_name": "AD HOC NEWS", "published_at": "2026-05-16T10:08:57", "published_display": "16 May 2026 10:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Highbridge (FBIO) reports 2.73M warrant-backed shares, 7.8% stake", "summary": "Highbridge Capital Management has filed an amended Schedule 13G, reporting beneficial ownership of 2.73 million Fortress Biotech (FBIO) shares, which are issuable upon the exercise of warrants. This accounts for a 7.8% stake in the company, based on 32.2 million outstanding share", "url": "https://www.stocktitan.net/sec-filings/FBIO/schedule-13g-a-fortress-biotech-inc-amended-passive-investment-disclo-248027762adf.html", "source_name": "Stock Titan", "published_at": "2026-05-15T10:38:56", "published_display": "15 May 2026 10:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights", "summary": "Fortress Biotech announced strong financial results for Q1 2026, reporting a consolidated net income of $108.4 million, driven by the FDA approval of ZYCUBO\u00ae for Menkes disease and the subsequent sale of its Priority Review Voucher for $205 million. The company also highlighted p", "url": "https://www.sahmcapital.com/news/content/fortress-biotech-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights-2026-05-14", "source_name": "Sahm", "published_at": "2026-05-15T09:10:01", "published_display": "15 May 2026 09:10", "sentiment": "positive", "sentiment_pct": 81, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Fortress Biotech: Q1 Earnings Snapshot", "summary": "Fortress Biotech Inc. (FBIO) reported strong financial results for its first quarter, with a net income of $110.4 million, or $2.82 per share. The biopharmaceutical company also recorded revenues of $16 million during the period. This financial snapshot was generated using data f", "url": "https://www.10tv.com/article/syndication/associatedpress/fortress-biotech-q1-earnings-snapshot/616-2daa848e-5814-4f2f-b276-e5c60458c7ff", "source_name": "10TV", "published_at": "2026-05-14T21:50:00", "published_display": "14 May 2026 21:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech, Inc. 1Q 2026: Revenue $15.92M, Net income $110.37M, EPS $2.82\u2014 10-Q Summary", "summary": "Fortress Biotech, Inc. reported strong first-quarter 2026 results, with revenue growing to $15.92M and net income attributable to common stockholders skyrocketing to $110.37M, resulting in a diluted EPS of $2.82. This significant improvement from the previous year's loss was larg", "url": "https://www.tradingview.com/news/tradingview:2dfa651bf209f:0-fortress-biotech-inc-1q-2026-revenue-15-92m-net-income-110-37m-eps-2-82-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-14T21:09:51", "published_display": "14 May 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech (NASDAQ: FBIO) turns Q1 2026 profit after $205M PRV sale", "summary": "Fortress Biotech reported a significant turnaround in Q1 2026, achieving a net income of $108.4 million due to the sale of a Rare Pediatric Disease Priority Review Voucher for $205 million, which generated a $158.9 million gain. The company also saw increased net revenue to $16.0", "url": "https://www.stocktitan.net/sec-filings/FBIO/8-k-fortress-biotech-inc-reports-material-event-cb2b93138583.html", "source_name": "Stock Titan", "published_at": "2026-05-14T20:38:56", "published_display": "14 May 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech posts $108.4M net income in Q1 2026, revenue $16.0M", "summary": "Fortress Biotech (FBIO) reported a significant Q1 2026 net income of $108.4 million, primarily driven by a $158.9 million gain from the sale of a priority review voucher. The company's consolidated net revenue reached $16.0 million, mainly from Journey Medical\u2019s dermatology produ", "url": "https://www.tradingview.com/news/tradingview:f4c447d16641e:0-fortress-biotech-posts-108-4m-net-income-in-q1-2026-revenue-16-0m/", "source_name": "TradingView", "published_at": "2026-05-14T20:09:51", "published_display": "14 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech stock (US32015L1035): Q1 earnings miss on revenue, but EMROSI shows momentum", "summary": "Fortress Biotech (FBIO) reported its Q1 2026 earnings, missing revenue expectations at $6.3 million but showing strong growth in its dermatology asset, EMROSI, which saw prescription volumes reach approximately 30,000. The company narrowed its net loss to $2.2 million from $4.1 m", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/fortress-biotech-stock-us32015l1035-q1-earnings-miss-on-revenue-but/69332697", "source_name": "AD HOC NEWS", "published_at": "2026-05-14T10:09:18", "published_display": "14 May 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights", "summary": "This press release from Fortress Biotech announces its financial results for the first quarter of 2026, along with recent corporate highlights. The report will detail the company's financial performance and significant developments during that period.", "url": "https://www.moomoo.com/hant/news/post/70034042/press-release-fortress-biotech-reports-first-quarter-2026-financial-results", "source_name": "Moomoo", "published_at": "2026-05-14T08:40:08", "published_display": "14 May 2026 08:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "(FBIOP) as a Liquidity Pulse for Institutional Tactics", "summary": "This article analyzes Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (NASDAQ: FBIOP) using AI models. It highlights weak near-term sentiment but long-term strength, with support being tested. The analysis provides institutional trading strat", "url": "https://news.stocktradersdaily.com/news_release/150/FBIOP_as_a_Liquidity_Pulse_for_Institutional_Tactics_051326125402_1778648042.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-13T00:54:00", "published_display": "13 May 2026 00:54", "sentiment": "positive", "sentiment_pct": 63, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TradingKey", "summary": "This page from TradingKey provides a detailed overview of Fortress Biotech Inc. (FBIO), including its stock price, market capitalization, and a navigation menu to various financial data, discussions, and analysis tools. It also offers information about TradingKey's services, such", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fbio/comments", "source_name": "TradingKey", "published_at": "2026-05-11T20:09:04", "published_display": "11 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Fortress Biotech Inc expected to post a loss of 22 cents a share - Earnings Preview", "summary": "Fortress Biotech Inc (FBIO) is anticipated to report a loss of 22 cents per share, according to this earnings preview. The article, provided by Refinitiv, gives a brief outlook on the company's upcoming financial results.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N41L2VA:0-fortress-biotech-inc-expected-to-post-a-loss-of-22-cents-a-share-earnings-preview/", "source_name": "TradingView", "published_at": "2026-05-09T01:09:34", "published_display": "09 May 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech (Nasdaq:FBIO) - Stock Analysis", "summary": "This Simply Wall St analysis of Fortress Biotech (FBIO) indicates the stock is currently undervalued by analysts, with earnings projected to grow significantly. However, the company faces financial risks including less than a year of cash runway and a small market capitalization.", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fbio/fortress-biotech", "source_name": "Simply Wall Street", "published_at": "2026-05-07T13:40:02", "published_display": "07 May 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fortress-biotech-participate-h-c-123000795.html", "source_name": "GlobeNewswire", "published_at": "2026-05-04T12:30:00+00:00", "published_display": "04 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Fortress (FBIOP) Market Conditions | Fortress Biotech pref posts 108.9% steep EPS miss - Healthcare Earnings Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPWTFjcE5mcGVzWXJzMTU1YUM0V3luQ3Q1V19oZk53NEdwRVJGYjh3QnJ6SjhJRnotRHdpeHNNTDZKbVdUN0lVbUt0ZkdYOGkyZWt4MjJ3WElwcm5rYU9heXlxc01lYlpTb0ljNXV6c2tiLVJpakJsUXpyU3RSa0RLbkhoTkxKTS1aQVRLOG9vVTJtUk9lUjJhU1kwX2JqNVdkM0NHdHFXQU02VVRZTTY3Zkc5VVZlbXJybVluVg?oc=5", "source_name": "newsline.com", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Fortress (FBIOP) Stock Rebounding | Price at $13.49, Down 0.70% - Active ETF Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPT2tPZ3pOUDVLYjVaLW1IWlhJMkJraVlZdG1NdFVGWVVNRDY1bUZSM1I2T09DaTE5cFZaMlpHUXR4QVY3TXBjeDdJVkZyS3VydEI3ZjZFUEt5R3lsTzJSZnV3NnJQMmw1QjlWNjJnY1lMVWtHT211OUNUMVNzWkxoMlE5bWtQMm01RDNDVzNKNXVNQTVCWWRnUFJQZ1V5NW1NM1RwX1JoejE4MGFo?oc=5", "source_name": "newsline.com", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech: Q4 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fortress-biotech-q4-earnings-snapshot-214658970.html", "source_name": "Associated Press", "published_at": "2026-03-31T21:46:58+00:00", "published_display": "31 Mar 2026 21:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fortress-biotech-reports-2025-financial-200500690.html", "source_name": "GlobeNewswire", "published_at": "2026-03-31T20:05:00+00:00", "published_display": "31 Mar 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPQi14VVlUSUNmM1JubXFxZ19jVkNBOWpkU01zWEt6Mm4zTnZwSXRhZ3pMVFhFSmhCQUp4ZHZxUjNsUnZ0cUR4UEhRZkI3aERudlFhdTZFcUFxOVJGb044bElybWk1a2VPbnpqRFdGSzBRRHphdlVQYjVmZVNKd2tERUxFcENqZ252YWYtSnhHRXFwcGxkYnVGekZJdW91QUMwUDVQcEVqd2JRNm8?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "FORTRESS BIOTECH INC 9.375% CUM RED PER PREF SER A USD25.00 Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAJBVV95cUxPS25OdXVCT3F0cF9VMkQ3bi14SE9lZkpPOVhHZ2hKVmFUbkxMcHlxNVJIUnBNXzc1TzY2R0JaWlFPNWd2bVZuOGkxTFdicDMwLWdEOFdsOVpCNmR1VHNLbFpyaHhZYkY1Q3p4c3lRRDEyUGlZTzhLUXJ3ZWJXV1AtdDhjLUlhME9BSV9zWWtnOFMySVhaQURDMGxiVzdfRFF6d2hMN3MydXVkbk5Yd0J0ZE9ZMzRvMFRubnhfd0xSZGhLRWRGcTdDeEVZZlRjM2pUcHJMb1pPQ095Vmp0RV9XTENFZXlJcVBGMTNXVjg0SVpwYTRkLWhNZXVadDFpV1FWRDJ2Ri0yeEhmcnRMamtBTFpFNENvX0YwWGszQjcxVmxTS1Bi?oc=5", "source_name": "Moomoo", "published_at": "2024-09-04T07:00:00+00:00", "published_display": "04 Sep 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQeS1IeHIzdHVGc1gxbVVEZFc5UENGMk9oWndCT3NRMkxjSTkyZVI1c1BkX1JkdDBUUTF2a3NKcTJ4eVc5NmRxRlFWYWJ2VGNiVU1JQlY2NW1CeW5SdmxhV2dHMndzY0RYVTNuU2I0anhMTXEyUHh4WllHVGlMS015OURNVTJUSmNUdDdlZmxaNA?oc=5", "source_name": "Market source", "published_at": "2024-07-05T07:00:00+00:00", "published_display": "05 Jul 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech 9.375 % Cum Conv Perp Red Pfd Registered Shs Series A Stock Forecast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSkFVX3lxTE5yN1BDLVBXLUdud0tQZzBhVDQ1UG81VXMwd1JESWU5MjVsY3ZJc2pHbk1KWVlNeTZFdzNpVjhPQWh0Z01jbE5VdXhn?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-15T02:21:16+00:00", "published_display": "15 Dec 2020 02:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Fortress Biotech Inc (FBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Fortress Biotech Inc (FBIO) has an earnings forecast score of 8.00, ranking 55th in the Pharmaceuticals industry. Analysts have set an average price target of $10.75, with most recommending a \"Buy\" trend for the stock. The expected revenue for the next quarter is $18.30M, and the", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fbio/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T06:40:18", "published_display": "19 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech (FBIO) AGM 2026 Summary", "summary": "Fortress Biotech's 2026 Annual General Meeting (AGM) was called to order by the Executive Chairman, President, and CEO. Key agenda items included the election of directors and the ratification of KPMG as the independent auditors for 2026, both of which were approved by shareholde", "url": "https://quartr.com/events/fortress-biotech-inc-fbio-agm-2026_F3HKeOdM", "source_name": "Quartr", "published_at": "2026-06-17T14:40:24", "published_display": "17 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc (FBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Fortress Biotech Inc's (FBIO) dividend and stock split history. It notes that no dividends have been distributed in the past five years. The article also details several stock merger events that occurred on October 9, 2023, with a 15:1 ratio.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fbio/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T07:40:24", "published_display": "17 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc (FBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article details Fortress Biotech Inc (FBIO)'s revenue breakdown by business segment for FY2023, FY2023Q4, FY2022, FY2022Q4, FY2021, and FY2019. Key products like Targadox\u00ae, Exelderm\u00ae, and Ximino\u00ae are highlighted with their respective revenue figures and proportions. The repo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fbio/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T07:40:24", "published_display": "17 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(FBIOP) Volatility Zones as Tactical Triggers", "summary": "This article from Stock Traders Daily provides a technical analysis of Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP), highlighting a near-term neutral outlook despite mid and long-term strength. It presents AI-generated trading stra", "url": "https://news.stocktradersdaily.com/news_release/101/FBIOP_Volatility_Zones_as_Tactical_Triggers_061526044002_1781512802.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-15T04:40:00", "published_display": "15 Jun 2026 04:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred Stock (FBIOP) Faces Resistance, Slides 2.3% in Quiet Session - Fibonacci Extension", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOREFSdWZib1NLQkowbGVLbnZFa0pvRG1RRUtlUXBJMzE2aHZ4Z01oaEFISHdYYjVOOS12Y1ZOc0xfMmpUWmhMN2tIQW9DaTZVd0FJNVNrWW9nZVBZM0E2X3NvYUlXdDdvWnh2VkFnR0FXZmF1V0wyR3h4ZjNLaDlyYUlTUDRsdFhDeHVZSXo0cFZzd3pjQVlHeEk2bEFkWGRBWW83c2tOWEgtZ1lTWTUwNi1Sd05EcGdaNGJsSHBFclNIZw?oc=5", "source_name": "newsline.com", "published_at": "2026-06-09T00:40:06+00:00", "published_display": "09 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred Stock (FBIOP) Pulls Back 2.3% as Shares Approach Key Support - Descending Triangle", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOcDV4S3RueVZmTFNIMzNXc3ZuZHY5YXI5cldiZTF3NHU3OVRVbU1nZzg1RFAxa0Z3dnhDemczLUpuUDZVNEs1ZzlvanFjQ255bkhsWF9FQ3haUk5rVTlZc0NQUUtTd3pJQnY4cHV0Rnd3TU9vd3otT19iZVJyd1VGV3lGOTFoWjI1dV9RYmlDdXlzYVJQVFRUc1l4QzdYRC0wMUpfMXZTNDJ6d2s1eHg2RmVEa3p6eGRIa1FTVHVGVVR2UEU?oc=5", "source_name": "newsline.com", "published_at": "2026-06-08T20:47:17+00:00", "published_display": "08 Jun 2026 20:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price-Driven Insight from (FBIOP) for Rule-Based Strategy", "summary": "This article provides a price-driven analysis for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (NASDAQ: FBIOP), indicating a strong overweight bias across all horizons. It identifies compelling upside potential due to the absence of resist", "url": "https://news.stocktradersdaily.com/news_release/1/Price-Driven_Insight_from_FBIOP_for_Rule-Based_Strategy_060426031002_1780557002.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-04T03:38:41", "published_display": "04 Jun 2026 03:38", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc stock (US32015L1035): Nasdaq-listed biotech moves in low-volume trade ahead of next earnings update", "summary": "Fortress Biotech Inc. (FBIO), a Nasdaq-listed biotech company, has experienced low-volume trading and modest price movements as investors await its next quarterly report. The company specializes in rare diseases and oncology, with its business model relying on commercial specialt", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/fortress-biotech-inc-stock-us32015l1035-nasdaq-listed-biotech-moves-in/69470220", "source_name": "Ad Hoc News", "published_at": "2026-06-02T10:32:40", "published_display": "02 Jun 2026 10:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred Stock (FBIOP) Surges 5.19%, Nears Key Resistance at $21.5 - Stock Picks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQVG9CdWZZa2pqZDhEa05ua0NxWkdfOU5USS03Yjk4cEJQbmtUcnU4MExJVW4wUG5VRDlvcGZKZjlwa1pmNExSUC1HZXJkSGhTUzhOSnB6NjVaLS15TzU3YTB1c1cwWTNUbVlPWlAxVWpXNWVKTGRUeUNGWHljbFNCVWJZQTEtZ2pCRW5HcnNWQVRBcldUbHEwWC1uLVZVSFZjWGRUSVpHd24zclBPaUpiSnRScW02bms?oc=5", "source_name": "newsline.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends? (FBIO)", "summary": "Fortress Biotech (FBIO) currently holds $256 million in cash and $39 million in debt, creating a strong balance sheet after a recent windfall from a Menkes disease drug sale. This positions the company to easily pay off $16 million in deferred FBIOP preferred dividends, which cou", "url": "https://seekingalpha.com/article/4910163-fortress-biotech-is-it-time-to-pay-deferred-preferred-stock-dividends", "source_name": "Seeking Alpha", "published_at": "2026-05-29T21:39:16", "published_display": "29 May 2026 21:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred (FBIOP) Rises 2.37%; Support and Resistance in Focus - Synthetic Long", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPTEp2d3hjZ2xPeEFwcDBGQmRFRnVhOFVySTNDZUYxMk9BWGRrRmhRVlJ2NUQtRVNJOTYxREdGTUt3STZzRDJIYmJkZHhJcU1wZmtZcHpTdkw4aFdzMGJ2RE95c2F2UHd0ZmtWNTZxNEZ6RkdyUHI4YTVtTFRuWUFrZzBvM2tHWmJnd1d6QktuandITTNHUjFMVzZlX09remdSNTVjU2NjY1FTeWZGZU5uRG4yRklyb21wNTNmX3RIM3dqX1h1?oc=5", "source_name": "The Legal Advocate", "published_at": "2026-05-28T20:47:08+00:00", "published_display": "28 May 2026 20:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Preferred Shares (FBIOP) Advance 2.45% as Support Holds Near $16 - Volume Breakout Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOcjVMRy11bDFrSnpid0FoZzNMN1h0RGtnM2paYlozUVpFVDg2WkNJa1lDSWh6WFFMNFpXcXhDV3NkdVMxZFM4MW8wdjlzdjFsNFVVTDhiSHI0Y3dsenpHby11eTk1RFYwcWE0dFUxcTdITDFjUlM3dlQ2SzJPZVc2b3llNW5NWE9LdmpQb2thRUxqYXJGVDZUM0VqdDREMVZzamltLXhnT1k3OGhhOTRWdmNpbnpMRnZs?oc=5", "source_name": "newsline.com", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(FBIOP) Price Dynamics and Execution-Aware Positioning", "summary": "This article analyzes Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (NASDAQ: FBIOP) using AI models. It highlights strong sentiment supporting an overweight bias despite elevated downside risk, providing institutional trading strategies tai", "url": "https://news.stocktradersdaily.com/news_release/141/FBIOP_Price_Dynamics_and_Execution-Aware_Positioning_052426020202_1779602522.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-24T02:10:44", "published_display": "24 May 2026 02:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech to Participate in A.G.P.\u2019s Annual Virtual Healthcare Conference", "summary": "Fortress Biotech, an innovative biopharmaceutical company, announced that its Chairman, President, and CEO, Lindsay A. Rosenwald, M.D., will participate in a fireside chat at A.G.P.\u2019s Annual Virtual Healthcare Conference on Wednesday, May 20, 2026, at 12:20 PM ET. The company foc", "url": "https://www.sahmcapital.com/news/content/fortress-biotech-to-participate-in-agps-annual-virtual-healthcare-conference-2026-05-18", "source_name": "Sahm", "published_at": "2026-05-19T07:09:36", "published_display": "19 May 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock", "summary": "This article provides details about Fortress Biotech, Inc.'s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) on the Nasdaq Stock Market. It briefly mentions the availability of financial data, news, community insights, and technical analysis for this speci", "url": "https://www.tradingview.com/symbols/NASDAQ-FBIOP/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-05-18T05:39:26", "published_display": "18 May 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Fortress Biotech, Inc. \u2013 NASDAQ:FBIO", "summary": "This article provides details on the number of shareholders for Fortress Biotech, Inc. (NASDAQ:FBIO). It appears to be a stub or a placeholder, as the actual numbers for \"Period,\" \"Value,\" \"Change,\" and \"Change %\" are explicitly missing from the content. The page also includes ge", "url": "https://www.tradingview.com/symbols/NASDAQ-FBIO/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-05-17T16:39:49", "published_display": "17 May 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech stock (US32015L1035): FDA setback hits Menkes drug while investors eye next catalysts", "summary": "Fortress Biotech has faced a setback after the FDA declined to approve CUTX-101, a Menkes disease treatment from its subsidiary Cyprium Therapeutics. This regulatory decision has put pressure on the company's valuation and rare-disease pipeline, impacting speculative investors. D", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/fortress-biotech-stock-us32015l1035-fda-setback-hits-menkes-drug-while/69349115", "source_name": "AD HOC NEWS", "published_at": "2026-05-16T10:08:57", "published_display": "16 May 2026 10:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Highbridge (FBIO) reports 2.73M warrant-backed shares, 7.8% stake", "summary": "Highbridge Capital Management has filed an amended Schedule 13G, reporting beneficial ownership of 2.73 million Fortress Biotech (FBIO) shares, which are issuable upon the exercise of warrants. This accounts for a 7.8% stake in the company, based on 32.2 million outstanding share", "url": "https://www.stocktitan.net/sec-filings/FBIO/schedule-13g-a-fortress-biotech-inc-amended-passive-investment-disclo-248027762adf.html", "source_name": "Stock Titan", "published_at": "2026-05-15T10:38:56", "published_display": "15 May 2026 10:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights", "summary": "Fortress Biotech announced strong financial results for Q1 2026, reporting a consolidated net income of $108.4 million, driven by the FDA approval of ZYCUBO\u00ae for Menkes disease and the subsequent sale of its Priority Review Voucher for $205 million. The company also highlighted p", "url": "https://www.sahmcapital.com/news/content/fortress-biotech-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights-2026-05-14", "source_name": "Sahm", "published_at": "2026-05-15T09:10:01", "published_display": "15 May 2026 09:10", "sentiment": "positive", "sentiment_pct": 81, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech: Q1 Earnings Snapshot", "summary": "Fortress Biotech Inc. (FBIO) reported strong financial results for its first quarter, with a net income of $110.4 million, or $2.82 per share. The biopharmaceutical company also recorded revenues of $16 million during the period. This financial snapshot was generated using data f", "url": "https://www.10tv.com/article/syndication/associatedpress/fortress-biotech-q1-earnings-snapshot/616-2daa848e-5814-4f2f-b276-e5c60458c7ff", "source_name": "10TV", "published_at": "2026-05-14T21:50:00", "published_display": "14 May 2026 21:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech, Inc. 1Q 2026: Revenue $15.92M, Net income $110.37M, EPS $2.82\u2014 10-Q Summary", "summary": "Fortress Biotech, Inc. reported strong first-quarter 2026 results, with revenue growing to $15.92M and net income attributable to common stockholders skyrocketing to $110.37M, resulting in a diluted EPS of $2.82. This significant improvement from the previous year's loss was larg", "url": "https://www.tradingview.com/news/tradingview:2dfa651bf209f:0-fortress-biotech-inc-1q-2026-revenue-15-92m-net-income-110-37m-eps-2-82-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-14T21:09:51", "published_display": "14 May 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech (NASDAQ: FBIO) turns Q1 2026 profit after $205M PRV sale", "summary": "Fortress Biotech reported a significant turnaround in Q1 2026, achieving a net income of $108.4 million due to the sale of a Rare Pediatric Disease Priority Review Voucher for $205 million, which generated a $158.9 million gain. The company also saw increased net revenue to $16.0", "url": "https://www.stocktitan.net/sec-filings/FBIO/8-k-fortress-biotech-inc-reports-material-event-cb2b93138583.html", "source_name": "Stock Titan", "published_at": "2026-05-14T20:38:56", "published_display": "14 May 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech posts $108.4M net income in Q1 2026, revenue $16.0M", "summary": "Fortress Biotech (FBIO) reported a significant Q1 2026 net income of $108.4 million, primarily driven by a $158.9 million gain from the sale of a priority review voucher. The company's consolidated net revenue reached $16.0 million, mainly from Journey Medical\u2019s dermatology produ", "url": "https://www.tradingview.com/news/tradingview:f4c447d16641e:0-fortress-biotech-posts-108-4m-net-income-in-q1-2026-revenue-16-0m/", "source_name": "TradingView", "published_at": "2026-05-14T20:09:51", "published_display": "14 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech stock (US32015L1035): Q1 earnings miss on revenue, but EMROSI shows momentum", "summary": "Fortress Biotech (FBIO) reported its Q1 2026 earnings, missing revenue expectations at $6.3 million but showing strong growth in its dermatology asset, EMROSI, which saw prescription volumes reach approximately 30,000. The company narrowed its net loss to $2.2 million from $4.1 m", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/fortress-biotech-stock-us32015l1035-q1-earnings-miss-on-revenue-but/69332697", "source_name": "AD HOC NEWS", "published_at": "2026-05-14T10:09:18", "published_display": "14 May 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights", "summary": "This press release from Fortress Biotech announces its financial results for the first quarter of 2026, along with recent corporate highlights. The report will detail the company's financial performance and significant developments during that period.", "url": "https://www.moomoo.com/hant/news/post/70034042/press-release-fortress-biotech-reports-first-quarter-2026-financial-results", "source_name": "Moomoo", "published_at": "2026-05-14T08:40:08", "published_display": "14 May 2026 08:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(FBIOP) as a Liquidity Pulse for Institutional Tactics", "summary": "This article analyzes Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (NASDAQ: FBIOP) using AI models. It highlights weak near-term sentiment but long-term strength, with support being tested. The analysis provides institutional trading strat", "url": "https://news.stocktradersdaily.com/news_release/150/FBIOP_as_a_Liquidity_Pulse_for_Institutional_Tactics_051326125402_1778648042.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-13T00:54:00", "published_display": "13 May 2026 00:54", "sentiment": "positive", "sentiment_pct": 63, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TradingKey", "summary": "This page from TradingKey provides a detailed overview of Fortress Biotech Inc. (FBIO), including its stock price, market capitalization, and a navigation menu to various financial data, discussions, and analysis tools. It also offers information about TradingKey's services, such", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fbio/comments", "source_name": "TradingKey", "published_at": "2026-05-11T20:09:04", "published_display": "11 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Inc expected to post a loss of 22 cents a share - Earnings Preview", "summary": "Fortress Biotech Inc (FBIO) is anticipated to report a loss of 22 cents per share, according to this earnings preview. The article, provided by Refinitiv, gives a brief outlook on the company's upcoming financial results.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N41L2VA:0-fortress-biotech-inc-expected-to-post-a-loss-of-22-cents-a-share-earnings-preview/", "source_name": "TradingView", "published_at": "2026-05-09T01:09:34", "published_display": "09 May 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech (Nasdaq:FBIO) - Stock Analysis", "summary": "This Simply Wall St analysis of Fortress Biotech (FBIO) indicates the stock is currently undervalued by analysts, with earnings projected to grow significantly. However, the company faces financial risks including less than a year of cash runway and a small market capitalization.", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fbio/fortress-biotech", "source_name": "Simply Wall Street", "published_at": "2026-05-07T13:40:02", "published_display": "07 May 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fortress-biotech-participate-h-c-123000795.html", "source_name": "GlobeNewswire", "published_at": "2026-05-04T12:30:00+00:00", "published_display": "04 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress (FBIOP) Market Conditions | Fortress Biotech pref posts 108.9% steep EPS miss - Healthcare Earnings Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPWTFjcE5mcGVzWXJzMTU1YUM0V3luQ3Q1V19oZk53NEdwRVJGYjh3QnJ6SjhJRnotRHdpeHNNTDZKbVdUN0lVbUt0ZkdYOGkyZWt4MjJ3WElwcm5rYU9heXlxc01lYlpTb0ljNXV6c2tiLVJpakJsUXpyU3RSa0RLbkhoTkxKTS1aQVRLOG9vVTJtUk9lUjJhU1kwX2JqNVdkM0NHdHFXQU02VVRZTTY3Zkc5VVZlbXJybVluVg?oc=5", "source_name": "newsline.com", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Fortress (FBIOP) Stock Rebounding | Price at $13.49, Down 0.70% - Active ETF Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPT2tPZ3pOUDVLYjVaLW1IWlhJMkJraVlZdG1NdFVGWVVNRDY1bUZSM1I2T09DaTE5cFZaMlpHUXR4QVY3TXBjeDdJVkZyS3VydEI3ZjZFUEt5R3lsTzJSZnV3NnJQMmw1QjlWNjJnY1lMVWtHT211OUNUMVNzWkxoMlE5bWtQMm01RDNDVzNKNXVNQTVCWWRnUFJQZ1V5NW1NM1RwX1JoejE4MGFo?oc=5", "source_name": "newsline.com", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech: Q4 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fortress-biotech-q4-earnings-snapshot-214658970.html", "source_name": "Associated Press", "published_at": "2026-03-31T21:46:58+00:00", "published_display": "31 Mar 2026 21:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/fortress-biotech-reports-2025-financial-200500690.html", "source_name": "GlobeNewswire", "published_at": "2026-03-31T20:05:00+00:00", "published_display": "31 Mar 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPQi14VVlUSUNmM1JubXFxZ19jVkNBOWpkU01zWEt6Mm4zTnZwSXRhZ3pMVFhFSmhCQUp4ZHZxUjNsUnZ0cUR4UEhRZkI3aERudlFhdTZFcUFxOVJGb044bElybWk1a2VPbnpqRFdGSzBRRHphdlVQYjVmZVNKd2tERUxFcENqZ252YWYtSnhHRXFwcGxkYnVGekZJdW91QUMwUDVQcEVqd2JRNm8?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FORTRESS BIOTECH INC 9.375% CUM RED PER PREF SER A USD25.00 Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAJBVV95cUxPS25OdXVCT3F0cF9VMkQ3bi14SE9lZkpPOVhHZ2hKVmFUbkxMcHlxNVJIUnBNXzc1TzY2R0JaWlFPNWd2bVZuOGkxTFdicDMwLWdEOFdsOVpCNmR1VHNLbFpyaHhZYkY1Q3p4c3lRRDEyUGlZTzhLUXJ3ZWJXV1AtdDhjLUlhME9BSV9zWWtnOFMySVhaQURDMGxiVzdfRFF6d2hMN3MydXVkbk5Yd0J0ZE9ZMzRvMFRubnhfd0xSZGhLRWRGcTdDeEVZZlRjM2pUcHJMb1pPQ095Vmp0RV9XTENFZXlJcVBGMTNXVjg0SVpwYTRkLWhNZXVadDFpV1FWRDJ2Ri0yeEhmcnRMamtBTFpFNENvX0YwWGszQjcxVmxTS1Bi?oc=5", "source_name": "Moomoo", "published_at": "2024-09-04T07:00:00+00:00", "published_display": "04 Sep 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQeS1IeHIzdHVGc1gxbVVEZFc5UENGMk9oWndCT3NRMkxjSTkyZVI1c1BkX1JkdDBUUTF2a3NKcTJ4eVc5NmRxRlFWYWJ2VGNiVU1JQlY2NW1CeW5SdmxhV2dHMndzY0RYVTNuU2I0anhMTXEyUHh4WllHVGlMS015OURNVTJUSmNUdDdlZmxaNA?oc=5", "source_name": "Market source", "published_at": "2024-07-05T07:00:00+00:00", "published_display": "05 Jul 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fortress Biotech 9.375 % Cum Conv Perp Red Pfd Registered Shs Series A Stock Forecast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSkFVX3lxTE5yN1BDLVBXLUdud0tQZzBhVDQ1UG81VXMwd1JESWU5MjVsY3ZJc2pHbk1KWVlNeTZFdzNpVjhPQWh0Z01jbE5VdXhn?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-15T02:21:16+00:00", "published_display": "15 Dec 2020 02:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 87, "total_relevant": 47, "sentiment_summary": {"positive": 9, "negative": 2, "neutral": 36, "score": 54, "total": 47, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 75, "events": [{"event": "earnings", "label": "Earnings", "weight": 11.49, "count": 22}, {"event": "general", "label": "Market update", "weight": 10.6, "count": 18}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.45, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 9, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 20.06, "latest_week": "2026-06-19", "one_week_move": -3.1, "four_week_move": 20.1, "twelve_week_move": 49.9, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.651901, "market_dynamics_buy_signal": false, "relative_strength": 55.707262, "fair_value_gap": 95.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 55.7078, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.1% over one week, +20.1% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "newsline.com", "count": 6}, {"label": "Market source", "count": 6}, {"label": "TradingView", "count": 5}, {"label": "TradingKey", "count": 4}, {"label": "Stock Traders Daily", "count": 4}, {"label": "Seeking Alpha", "count": 2}, {"label": "Sahm", "count": 2}, {"label": "AD HOC NEWS", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 40}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 22}, {"label": "Market update", "count": 18}, {"label": "Deals and strategy", "count": 2}, {"label": "Guidance", "count": 2}, {"label": "Balance sheet", "count": 2}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "40", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-3.1% over one week, +20.1% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Fortress Biotech Inc (FBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates"}], "updated_at": "2026-06-22T05:11:22.385231+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}